title: Lipodystrophy and serum lipid abnormalities in HIV-positive sub-Saharan population on ART.
abstract: To evaluate whether racial factors may be involved in the development of ART-induced lipodystrophy and/or lipid serum abnormalities, we carried-out a case-control study on all 23 consecutive anti-HIV-positive sub-Saharan black African patients observed from September 20fc01 to December 2001 ('Cases') and 23 Caucasian 'Controls' pair-matched for sex, age (+/-5 years), number of CD4 cells (+/-100 cells), clinical stage of HIV infection, overall duration (+/-3 months) of anti-retroviral treatment and type and duration (+/-3 months) of the last anti-retroviral regimen. The cases, as compared with the controls, less frequently showed lipodystrophy (4.4 vs. 65.2%, P<0.001) and hypertriglyceridemia (8.8 vs. 56.5%, P<0.005), whereas the prevalence of subjects with hypercholesterolemia was similar in the two groups (30 and 39.1%, respectively). Overall, the prevalence of patients lacking both lipodystrophy and serum lipid abnormalities was markedly higher for the cases than for the controls (69.5 vs. 13%, P<0.001). This study seems to indicate that anti-retroviral-induced lipodystrophy and hypertriglyceridemia may be associated to some racial factor.
authors.affiliation: Department of Public Medicine, Section of Diagnosis and Treatment of AIDS, Second University of Naples, Italy.
authors.forename: Pietro
authors.initials: P
authors.lastname: Filippini
authors.forename: Carlo
authors.initials: C
authors.lastname: Scolastico
authors.forename: Martina
authors.initials: M
authors.lastname: Battaglia
authors.forename: Cesare
authors.initials: C
authors.lastname: Nacca
authors.forename: Nicola
authors.initials: N
authors.lastname: Coppola
authors.forename: Giovanni
authors.initials: G
authors.lastname: Rossi
authors.forename: Raffaella
authors.initials: R
authors.lastname: Pisapia
authors.forename: Salvatore
authors.initials: S
authors.lastname: Martini
authors.forename: Michele
authors.initials: M
authors.lastname: Imparato
authors.forename: Caterina
authors.initials: C
authors.lastname: Sagnelli
authors.forename: Felice
authors.initials: F
authors.lastname: Piccinino
authors.forename: Evangelista
authors.initials: E
authors.lastname: Sagnelli
mesh_terms: D000328:Adult; D017954:Africa South of the Sahara; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D044383:Black People; D016022:Case-Control Studies; D004359:Drug Therapy, Combination; D005260:Female; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006679:HIV Seropositivity / Q000150:complications* / Q000188:drug therapy / Q000208:ethnology; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000453:epidemiology / Q000208:ethnology; D006801:Humans; D006937:Hypercholesterolemia / Q000139:chemically induced / Q000453:epidemiology / Q000208:ethnology; D015228:Hypertriglyceridemia / Q000139:chemically induced / Q000453:epidemiology / Q000208:ethnology; D007558:Italy; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D044465:White People
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D008055:Lipids; D018894:Reverse Transcriptase Inhibitors